This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging is exhibiting the CT Laser Mammography (CTLM®) system at the Arab Health Congress 2012 medical conference, January 23-26, 2012 at the Dubai International Convention & Exhibition Centre, in Dubai, United Arab Emirates (UAE).
The Arab Health Exhibition and Congress (AHEC) is the largest healthcare exhibition and congress in the Middle East. AHEC provides an unrivalled platform for the world’s leading manufacturers, wholesalers and distributors to meet the medical and scientific community from the Middle East and beyond. Over
3000 exhibitors from over 100 countries and more than 70,000 healthcare professionals from across the world are expected to attend. Arab Health covers all aspects of the healthcare industry in the Middle East. Medical professionals, government officials, wholesalers, dealers and distributors converge on the Dubai International Exhibition Centre every year for the regions main event for the healthcare industry.
About Imaging Diagnostic Systems, Inc.Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM
®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and shows the process of angiogenesis, which usually accompanies tumor growth. The CTLM system has received international certifications and licenses from the European CE mark, CMDCAS Canadian Health screening, China SFDA, India, UL, and ISO 13485. The Company is seeking US marketing clearance from the FDA through the Premarket approval (PMA) process.
For more information, visit our website:
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.